Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo  by Hayami, Tadashi et al.
Speci¢c loss of chondromodulin-I gene expression in chondrosarcoma
and the suppression of tumor angiogenesis and growth by its
recombinant protein in vivo
Tadashi Hayamia, Chisa Shukunamib, Kaori Mitsuic, Naoto Endoa, Kunihiko Tokunagaa,
Jun Kondoc, Hideaki E. Takahashia, Yuji Hirakib;*
a Department of Orthopaedic Surgery, Niigata University School of Medicine, Niigata 951-8510, Japan
b Department of Molecular Interaction and Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Shogoin-Kawahara-cho,
Sakyo-ku, Kyoto 606-8507, Japan
cResearch Center, Mitsubishi Chemical Corporation, Kanagawa 227-0033, Japan
Received 18 May 1999; received in revised form 24 July 1999
Abstract Chondromodulin-I (ChM-I) was previously identified
as an angiogenesis inhibitor in cartilage. Here, we demonstrated
that the level of ChM-I transcripts was substantially reduced to
100 or even less in the lower-grade chondrosarcomas, in articular
cartilage or other benign cartilage tumors. We implanted human
chondrosarcoma OUMS-27 cells into nude mice that repro-
ducibly produced tumors with cartilaginous matrix. Tumor-
induced angiogenesis was evident when the tumors were excised
30 days after implantation. However, the local administration of
recombinant human ChM-I almost completely blocked vascular
invasion and tumor growth in vivo. Moreover, ChM-I also
inhibited the growth of HT-29 colon adenocarcinoma in vivo,
implying its therapeutic potential for solid tumors.
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1. Introduction
Vascularity of tissues is regulated by the balance of the
cumulative levels of inducer and inhibitor signals that main-
tain the endothelial cells in the alternative ‘angiostatic’ and
‘angiogenic’ states[1,2]. Thus, the angiogenic switching could
be activated either by increasing angiogenic inducers or by
reducing inhibitors. Cartilage is avascular and markedly re-
sistant to vascular invasion. Despite the apparent avascular-
ity, several angiogenic molecules have been described in car-
tilage, including ¢broblast growth factor (FGF) [3]. Due to an
intrinsic inhibitor [4], cartilage remains avascular except dur-
ing endochondral bone development. When chondrocytes be-
come hypertrophic and calci¢ed, capillaries invade from the
surrounding periosteum and trigger the replacement of carti-
lage by bone. The angiogenic switching of cartilage from ‘an-
giostatic’ to ‘angiogenic’ thus takes place at a precise stage
during development. However, no tissue-speci¢c macromole-
cule explicable for the angiogenic resistance of cartilage has
been identi¢ed.
We previously isolated a novel endothelial cell growth in-
hibitor, chondromodulin-I (ChM-I), from fetal bovine carti-
lage [5]. It is a 25 kDa glycosylated protein that inhibits an-
giogenesis in the chick chorioallantoic membrane in vivo [6].
In situ hybridization de¢ned the speci¢c expression of ChM-I
transcripts within the avascular zone of cartilage in developing
bone [5,7]. However, the expression of the gene was markedly
reduced in the late hypertrophic and calci¢ed zones of carti-
lage, allowing for vascular invasion. The localization of ChM-
I protein completely overlapped the area of its gene expression
[5]. The secreted mature ChM-I was accumulated in the inter-
territorial space of cartilage matrix so that an anti-angiogenic
barrier of ChM-I could wrap up the angiogenic FGF-contain-
ing pericellular space [5,8].
A considerable body of evidence has suggested that the
growth of solid tumor and metastasis require persistent new
blood vessel growth [1]. A malignant cartilage-forming tumor
is not an exception. As we previously reported [7,9], normal
cartilage contains abundant ChM-I transcripts in comparison
to those for other growth factors. However, during the mo-
lecular cloning of human ChM-I cDNA [6], we noticed that
expression of the ChM-I gene was extremely low in chondro-
sarcoma (CS). Transcripts for ChM-I were hardly detectable
in CS even in the tissues from the di¡erentiated type lesion
(grade I). Thus, we hypothesized that the marked reduction of
ChM-I expression is involved in loss of the ‘anti-angiogenic’
property of cartilage during malignant transformation. In this
study, we ¢rst compared the level of ChM-I mRNA expressed
in CS with those in normal articular and other benign tumors.
We then examined whether the anti-angiogenic properties
could be restored in tumors by local administrations of re-
combinant human ChM-I (rhChM-I) protein.
2. Materials and methods
2.1. Materials and clinical samples
rhChM-I was expressed in Chinese hamster ovary cells and puri¢ed
from the culture supernatant to homogeneity by sequential chroma-
tography, as described [6]. Clinical samples were obtained from the
patients with informed consent. Six cases with CS (grade I periosteal
CS: two cases, grade I CS: three cases, grade II CS: one case), six
cases with enchondroma (Ench), six cases with exostosis (Exo) and
¢ve cases with articular cartilage (AC) were examined. Each specimen
was processed separately for pathological examination and for mRNA
extraction. Sections were evaluated by a hospital sta¡ pathologist.
2.2. Cell culture
Human CS OUMS-27 cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium containing 10% fetal bovine serum (FBS) at 37‡C in
5% CO2 in air [10]. HCS-TG cells were maintained in K-modi¢ed
Eagle’s medium (KMEM) containing 20% FBS at 37‡C in 5% CO2
in air. AC was obtained from the femoral head of a 51 year old female
who was su¡ering from osteoarthritis and underwent a total hip ar-
throplasty. Chondrocytes were then isolated by sequential digestions
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with 0.1% EDTA for 20 min, 0.2% trypsin for 1 h and 0.15% colla-
genase for 3 h [5]. The cells were grown in KMEM containing 10%
FBS at 37‡C in 5% CO2 in air. The medium was replaced every other
day.
2.3. Northern blot analysis
Total RNA was prepared from various human tissues and cultured
cells by the single-step method of Chomczynski and Sacchi [11]. Total
RNA (20 Wg) was denatured with 6% formaldehyde, separated by 1%
agarose electrophoresis and transferred onto Nytran membranes
(Schleicher and Schuell, Germany). Hybridization was performed
overnight at 42‡C with an appropriate probe (106 cpm/ml) as previ-
ously described [7]. Hybridization probes were prepared by the ran-
dom primer method with a BcaBEST Labelling kit (Takara, Japan)
using the appropriate cDNA fragments: a 1.4 kb EcoRI fragment of
pKT1180 [7] for K1(II) collagen mRNA and a 0.9 kb EcoRI fragment
of pCRII-hChM-I [6] for ChM-I mRNA. The ¢lters were washed
twice for 15 min at 55‡C in 0.1USSPE and 0.1% SDS and exposed
to Kodak X-OMAT ¢lm at 380‡C.
2.4. Reverse transcription (RT)-PCR and competitive PCR
To correct for any variation in RNA content and cDNA synthesis
between the di¡erent preparations, samples were equalized on the
basis of their L-actin content which was determined by using the
human L-actin Competitive PCR set (Takara, Tokyo, Japan) in ac-
cordance with the manufacturer’s instructions. First strand cDNA
was synthesized using SuperScript II RNAse H3 Reverse Transcrip-
tase (Gibco, Grand Island, NY, USA) with the corrected amount of
total RNA isolated from human tissues or cultured cells according to
the manufacturer’s instructions. Portions of total RNA were reverse-
transcribed. For RT-PCR, aliquots of 1/20 of the cDNA were used to
amplify ChM-I, K1(II) collagen, aggrecan and L-actin genes. The fol-
lowing primer sets were synthesized: 5P-CATCGGGGCCTTC-
TACTTCT-3P and 5P-GGCATGATCTTGCCTTCCAG-3P for ChM-
I mRNA [6], 5P-AACTGGCAAGCAAGGAGACA-3P and 5P-AG-
TTTCAGGTCTCTGCAGGT-3P for K1(II) collagen [12], 5P-ATGCC-
CAAGACTACCAGTGG-3P and 5P-TCCTGGAAGCTCTTCTCA-
GT-3P for aggrecan [12], 5P-AGCCATGTACGTTGCTA-3P and 5P-
AGTCCGCCTAGAAGCA-3P for L-actin [13]. Expected sizes of the
PCR products were 312, 621, 501 and 800 bp for ChM-I, K1(II)
collagen, aggrecan and L-actin, respectively. For the competitive
PCR analysis of ChM-I mRNA, the 479 bp competitive template
for human ChM-I was generated using the composite primers (5P-
CATCGGGGCCTTCTACTTCTCAAGTTTCGTGAGCTGATTG-3P
and 5P-GGCATGATCTTGCCTTCCAGTTGAGTCCATGGGGA-
GCTTT-3P) with a PCR MIMICTM Construction kit (Clontech,
CA, USA). One-¢ftieth of the product was re-ampli¢ed by using the
gene-speci¢c primer described above. Following the second PCR am-
pli¢cation, the competitive template was puri¢ed by Chroma
SPIN+TE-100 and diluted to 100 attomol/Wl for competitive experi-
ments. A ¢xed amount of cDNA was co-ampli¢ed with serial loga-
rithmic dilutions of the competitive template (from 1 to 1036 attomol/
Wl). The competitive template yields a larger PCR product of 479 bp.
The ampli¢cation reaction was carried out with initial denaturation at
94‡C for 5 min, 35 cycles of denaturation at 94‡C for 45 s, annealing
at 60‡C for 45 s, extension at 72‡C for 90 s and a ¢nal extension at
72‡C for 4 min. The PCR products were electrophoresed on a 1.5%
agarose gel containing ethidium bromide and photographed. The £u-
orescence intensity of each PCR product was estimated on NIH image
1.60, as previously described [14].
C
Fig. 1. Expression of ChM-I mRNA in human chondrogenic tumors
and AC. Total RNA was isolated from human CS, Ench, Exo and
AC. A: Reverse-transcribed cDNA was ampli¢ed by PCR using
primer pairs speci¢c for human L-actin, K1(II) collagen, aggrecan or
ChM-I. B: The relative level of ChM-I mRNA was estimated by
competitive PCR using cDNA from CS (grade I) and other cartila-
ginous tissues. Each reverse-transcribed cDNA was co-ampli¢ed by
gene-speci¢c primers in the presence of a 10-fold dilution series of
competitive template (upper panels). Estimated ChM-I mRNA levels
were plotted in a logarithmic scale with means þ S.D.s (n = 6 for
grade I CS, n = 6 each for Ench and Exo and n = 5 for AC) in the
lower panel. C: Total RNA (20 Wg/lane) isolated from human CS
cells HCS-TG (lane 1), OUMS-27 (lane 2) or human articular chon-
drocytes (lane 3) was separated by a 1% agarose gel for Northern
blot analysis. The transferred ¢lter was hybridized with human
ChM-I cDNA (upper panel) or rat K1(II) collagen cDNA (lower
panel). Equivalent loading of RNA was veri¢ed by ethidium bro-
mide staining (bottom panel). The positions of 28S and 18S riboso-
mal RNAs are indicated. The nucleotide sequence of human ChM-I
cDNA is available from the GenBank database under accession
numbers AB005999 and AB006000.
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2.5. Xenograft tumor models
Cultured OUM-27 cells (5U106 cells) in 0.1 ml phosphate-bu¡ered
saline (PBS) were inoculated subcutaneously in the back of 4 week old
Balb/c nu/nu mice. When the tumors developed at the injection sites
to become about 45 mm3 in volume (6 days after inoculation), mice
were randomized into two groups. One group received 5 Wg rhChM-I
in 50 Wl PBS, injected subcutaneously around the tumor daily for the
initial 5 days. The other group received PBS alone. Tumor volumes
were determined as width2UlengthU0.52 [15]. At the last time point,
tumors were excised and ¢xed for histological examinations. Similarly,
nude mice were inoculated by subcutaneous injection of HT-29 cells
(3.5U106 cells). When the tumor volume reached about 75 mm3, 11
days after inoculation, each mouse was injected with 20 Wl PBS alone
or PBS containing 20 Wg rhChM-I, daily for the initial 5 days.
3. Results and discussion
CSs have been traditionally divided into three histological
grades [16]. Low-grade lesions infrequently metastasize. How-
ever, when they do, it is usually to the lung and other areas of
the body through the invaded capillaries [16]. Although high-
grade (grade III) lesions are characterized by the most atypical
matrix, low-grade CSs are essentially indistinguishable from
growing Enchs. CSs of grades I and II excised from patients
expressed the cartilage-speci¢c matrix components such as
type II collagen and aggrecan at a level similar to those in
benign tumors and normal AC (Fig. 1A). Consequently, the
biochemical techniques have failed to help in the most di⁄cult
discrimination of the low-grade malignant entities [16].
Interestingly, the expression of ChM-I transcripts was only
barely detectable even in low-grade CSs, while they were read-
ily detected in Ench or Exo as well as normal AC (Fig. 1A).
The competitive PCR revealed a striking di¡erence in the
ChM-I mRNA level between CS and other specimens. Grade
I CSs contained ChM-I mRNA only at a level from 1/100 to
1/3500 of AC, while Ench contained a similar level of ChM-I
mRNA to normal cartilage (Fig. 1B). Exo expressed the tran-
scripts a little less than AC. On the other hand, there was no
detectable di¡erence in the content of type II collagen and
aggrecan transcripts (data not shown), indicating that ChM-
I is one of the most sensitively a¡ected genes by the malignant
transformation of cartilage. Further study on the basis of a
larger number of clinical samples, which is now underway,
may enable us to distinguish low-grade CSs from Enchs in
terms of the ChM-I gene expression.
Among a few human CS cell lines available, we examined
the expression of ChM-I mRNA in HCS-TG and OUMS-27
derived from grade III CS by Northern blotting and it was
compared to articular chondrocytes in primary culture (Fig.
1C). Although HCS-TG was devoid of type II collagen ex-
pression, OUMS-27 maintained the di¡erentiated phenotype
of chondrocytes which included an active synthesis of matrix
metachromatically stained with toluidine blue and the expres-
sion of type I, type II and type III collagens [10]. The cells
grew, taking on the elongated polygonal shape in monolayer
culture, and formed cartilage-like nodules after reaching con-
£uence. However, the expression of ChM-I mRNA was also
absent in these cell lines (Fig. 1C).
The balance hypothesis on angiogenic switching [1] may
predict that cartilaginous tissue becomes angiogenic to allow
for vascular invasion by the loss or withdrawal of anti-angio-
genic molecules even without any change in the level of an-
giogenic molecules such as FGF-2. In fact, intralesional ad-
ministration of anti-FGF-2 monoclonal antibody inhibited the
growth and vascularization of rat CS in vivo [17]. Then, it
must be similarly possible to restore the angiogenic resistance
in tumors by the supplementation of ChM-I protein. As we
demonstrated previously [7], exogenously added ChM-I pro-
tein inhibited the vascular invasion into cartilage, ectopically
induced by demineralized bone matrix in vivo, leading to the
suppression of bone formation [7]. Taking advantage of the
OUMS-27 xenograft tumor model [10], we tested our hypoth-
Fig. 2. E¡ect of rhChM-I on OUMS-27 human CS xenografts in
nude mice. OUMS-27 cells (5U106 cells) were inoculated subcutane-
ously in the back of 4 week old nude mice. A: When the tumor
volume reached about 45 mm3 after inoculation, each mouse was
injected with 50 Wl PBS alone (E) or 50 Wl PBS containing 5 Wg
rhChM-I (F) around the tumor for the initial 5 days indicated by
arrows. Values represent means þ S.D. (n = 5). B: Gross appearance
of tumors excised on day 29. Tumors were treated with PBS alone
(upper panel) or with rhChM-I (lower panel) for the initial 5 days.
C: A cross-section of the representative tumor treated with PBS
alone (upper panel) or with rhChM-I (lower panel). Bars represent
5 mm in B and C.
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esis by the administration of rhChM-I. When OUMS-27 cells
formed a tumor about 45 mm3 in size, mice received 5 Wg
rhChM-I dissolved in PBS at the site of the tumor for the
initial 5 days. In contrast to the control mice receiving PBS
alone, the tumor size was signi¢cantly suppressed (Fig. 2A).
Fig. 2B shows all of the tumor tissues excised from mice (¢ve
in each experimental group) used on day 29. The wet weight
(156 þ 48 mg on average) was about 30% of that in the control
mice (492 þ 100 mg on average). As shown in the cross-sec-
tions (Fig. 2C), tumors in the control mice allowed for a
considerable amount of capillary invasion, whereas those in
the treated mice did not.
Vascular invasion into cartilage may require a complex ser-
ies of events including an abnormal setting of angiogenic
switching as well as an inappropriate matrix organization.
Low-grade CSs have only a subtle anomaly in their extracel-
lular matrices and are free of any appreciable invasion by
capillaries. Higher-grade CSs are accompanied by the loss of
major matrix components such as type II collagen as exem-
pli¢ed by HCS-TG cells (Fig. 1C). Loss of ChM-I expression
seems an important prerequisite for acquisition of an angio-
genic property in CS, prior to the atypical matrix formation.
Supplementation of exogenous ChM-I protein resulted in
restoration of the anti-angiogenic property (Fig. 2B,C).
O’Reilly and coworkers identi¢ed anti-angiogenic peptides
termed angiostatin and endostatin in tumor-bearing mice
[15,18]. These peptides were released from plasminogen and
type XVIII collagen by a mechanism as yet unidenti¢ed. Ad-
ministration of these peptides resulted in tumor suppression in
mice, suggesting that cartilage-derived angiogenesis inhibitor
ChM-I can generally be applicable for the growth suppression
of solid tumors. We thus administered rhChM-I at the tumor
site of mice implanted with human colon adenocarcinoma
HT-29 cells (Fig. 3). When tumors grew to about 75 mm3
in size, 20 Wg rhChM-I was injected for 5 days. The tumor
growth was evidently suppressed. As we suggested [5], ChM-I
is localized in cartilage matrix and bound to anchoring mol-
ecules as a complex. The presence of anchoring molecules in
cartilaginous matrix may account for the e¡ective suppression
of CS, when compared to that of HT-29 colon carcinoma.
Identi¢cation of anchoring molecules and the cell-surface re-
ceptor may prove the usefulness of ChM-I as a therapeutic
agent.
At this moment, it is not known how the expression of
ChM-I mRNA was lost or suppressed in CSs. However, Ya-
maguchi and coworkers reported that local recurrence of CSs
was signi¢cantly associated with loss of heterozygosity on 13q
and/or 17p, indicating the presence of the retinoblastoma (Rb)
and/or p53 gene mutations [19]. The human ChM-I gene was
mapped on chromosome 13 q14-21 by £uorescence in situ
hybridization (submitted elsewhere). The NCBI database re-
vealed that the ChM-I gene (the human genomic map marker:
SHGC-31236) was mapped closely to the Rb gene (SHGC-
12474). The mouse ChM-I gene was also mapped at D3 on
chromosome 14, the region that contained the Rb gene locus
(C. Shukunami, unpublished data). The available evidence
suggests a cooperative role for the Rb and p53 tumor sup-
pressors in growth signaling and that the need for angiogenic
factors is balanced with the elimination, via mutation, of p53
[20]. Human CS OUMS-27 xenograft tumor was apparently
angiogenic (Fig. 2), while expression of the ChM-I gene could
not be detected in OUMS-27 cells by either Northern blot
(Fig. 1C) or RT-PCR. Kunisada and coworkers recently de-
scribed that OUMS-27 cells bear the mutant type p53 gene
[10], suggesting that p53 tumor suppressor may participate in
the ChM-I gene expression in cartilage. As reported [20], mu-
tations in the p53 gene were never selected in teratocarcinoma.
In fact, the teratocarcinoma-derived chondrogenic cell line
ATDC5 expressed ChM-I mRNA in a manner dependent
on cartilage di¡erentiation [7]. Experiments are currently
underway to elucidate the role of the Rb and p53 tumor
suppressors in ChM-I gene expression.
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